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Gamma interferon (IFN-) plays a critical role in the protective immune responses against mycobacteria.
We previously cloned a cDNA coding for guinea pig IFN- (gpIFN-) and reported that BCG vaccination
induced a significant increase in the IFN- mRNA expression in guinea pig cells in response to living
mycobacteria and that the virulent H37Rv strain of Mycobacterium tuberculosis stimulated less IFN- mRNA
than did the attenuated H37Ra strain. In this study, we successfully expressed and characterized recombinant
gpIFN- with a histidine tag at the N terminus (His-tagged rgpIFN-) in Escherichia coli. rgpIFN- was
identified as an 18-kDa band in the insoluble fraction; therefore, the protein was purified under denaturing
conditions and renatured. N-terminal amino acid sequencing of the recombinant protein yielded the sequence
corresponding to the N terminus of His-tagged gpIFN-. The recombinant protein upregulated major histo-
compatibility complex class II expression in peritoneal macrophages. The antiviral activity of rgpIFN- was
demonstrated with a guinea pig fibroblast cell line (104C1) infected with encephalomyocarditis virus. Inter-
estingly, peritoneal macrophages treated with rgpIFN- did not produce any nitric oxide but did produce
hydrogen peroxide and suppressed the intracellular growth of mycobacteria. Furthermore, rgpIFN- induced
morphological alterations in cultured macrophages. Thus, biologically active rgpIFN- has been successfully
produced and characterized in our laboratory. The study of rgpIFN- will further increase our understanding
of the cellular and molecular responses induced by BCG vaccination in the guinea pig model of pulmonary
tuberculosis.
Tuberculosis remains a global health problem, in part be-
cause of its occurrence in populations where human immuno-
deficiency virus/AIDS is also highly prevalent and due to the
emergence of multidrug-resistant strains (22). The only vaccine
available for tuberculosis is Mycobacterium bovis BCG; how-
ever, its efficacy has varied widely in clinical trials (4). Effector
mechanisms in antimycobacterial immunity involve macro-
phages and lymphocytes that act in concert with the help of
costimulatory molecules and molecular mediators such as cy-
tokines and chemokines (1). Macrophages act as the primary
phagocytic cells for early clearance of mycobacteria. It is
known that the immune response against Mycobacterium tu-
berculosis is mediated primarily by CD4 and CD8 T cells but
also involves other cell types, including NK cells (14, 33, 39).
Both gamma interferon (IFN-) and tumor necrosis factor
alpha (TNF-) have been identified as important cytokines
acting at the effector level of resistance to mycobacteria.
TNF- plays an important role in the formation and mainte-
nance of granulomas and, along with IFN-, activates macro-
phages to produce effector molecules such as reactive oxygen
and nitrogen intermediates (15, 17, 27). It is also known that
interleukin-12 (IL-12) and IL-23 (18, 46) contribute to the host
response to mycobacteria by enhancing the production of
IFN- and thus the development of Th1 immunity.
The importance of IFN- in antimycobacterial immunity has
been well documented. For example, IFN- is known to acti-
vate macrophages by upregulating major histocompatibility
complex (MHC) class II molecules, as well as to induce effector
molecules such as reactive nitrogen intermediates in murine
and human cells (45, 47). Several studies indicate that activa-
tion of monocytes and macrophages by IFN- results in effec-
tive growth restriction and clearance of mycobacteria (11–13).
Treatment of mice with neutralizing antibodies to TNF- and
IFN- prevented cellular infiltration and reduced the expres-
sion of proinflammatory and regulatory cytokines such as
TNF-, IFN-, macrophage inflammatory protein 1, IL-1,
and IL-10 (15). Similarly, disruption of the mouse IFN- gene
or the IFN- receptor gene resulted in an exacerbation of
disease after M. tuberculosis or M. bovis infection, reduced
expression of MHC class II antigens on macrophages, and
lethality in mice given sublethal doses (5, 6, 23, 24, 25). Fur-
thermore, humans with a mutation in the IFN- receptor or
IFN- receptor signal-transducing chain developed dissemi-
nated mycobacterial infections (9, 41).
The role of IFN- in the guinea pig model of low-dose
pulmonary infection has not been studied due to the lack of
recombinant protein and antibody. We have found that BCG
vaccination induced a significant increase in IFN- mRNA
expression in spleen or lymph node cells stimulated with in-
creasing doses of purified protein derivative or M. tuberculosis
H37Ra or H37Rv, compared to cells from naive animals, by
using a guinea pig IFN- (gpIFN-) cDNA clone (21). The
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purpose of this study was to express and purify recombinant
gpIFN- (rgpIFN-) protein and test its bioactivity based on its
ability to activate macrophages. The results from these studies
indicate that treatment with rgpIFN- upregulates MHC class
II expression, induces H2O2 production, restricts the growth of
virulent M. tuberculosis in peritoneal cells, and reduces the
cytopathic effect (CPE) in a guinea pig cell line infected with
encephalomyocarditis virus (EMCV).
MATERIALS AND METHODS
Cloning and expression of rgpIFN-. The plasmid chosen for expression of
rgpIFN- was a pQE-30 derivative (QIAGEN, Valencia, CA), and the protocol
used was essentially the same as that used earlier in our laboratory for rgpTNF-
and rgpIL-8 expression (29, 32). The plasmid was originally engineered by Mag-
nus Hook (TAMU-HSC IBT, Houston, TX) to include a thrombin cleavage site,
THR, between the six-His tag and the multiple cloning sites. gpIFN- cDNA
provided by one of us (T.Y.) was cloned into the pQE-30 multiple cloning site.
Escherichia coli strain M15 transformed with pQE-30/gpIFN- was grown at
37°C for approximately 1.5 h (optical density at 600 nm [OD600]  0.7) in
Luria-Bertani medium containing 100 g/ml ampicillin and 25 g/ml kanamycin
(Sigma). Induction of protein was done with 1 mM isopropyl--D-thiogalactopy-
ranoside (IPTG; Sigma), and 5 h later, the bacterial cells were harvested by
centrifugation at 4,000  g for 20 min. The cell pellet was frozen at 80°C. An
18-kDa band in the insoluble fraction was identified as a putative six-His–
rgpIFN- by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis. Cleared lysates (CL) were prepared by lysing the pellet under
denaturing conditions by the QIAGEN protocol in the presence of 10 mM
benzamidine to limit protease activity. The supernatant collected after centrifu-
gation was mixed with a 50% Ni-nitrilotriacetic acid slurry (QIAGEN) and
purified on polypropylene columns (QIAGEN). The immobilized rgpIFN- was
washed, and the protein was eluted in elution buffer (100 mM NaH2PO4, 10 mM
Tris-Cl, pH 4.5) in the presence of 8 M urea. Renaturation of the denatured
protein was carried out by dropwise addition of 10 ml of eluted protein to 100 ml
of dilution buffer (50 mM Tris, 50 mM NaCl, pH 8.0) containing 14 l of
-mercaptoethanol in the absence of urea. The folded protein solution was left
for 2 to 4 h at room temperature (RT) and transferred to 4°C. Protein was
concentrated in Amicon Ultra-15 centrifugal filter devices (Millipore Corp.,
Bedford, MA) by spinning 15 ml of sample for 50 min at 2,635  g at 4°C. The
protein content was determined by the Bradford assay (Bio-Rad, Richmond,
CA). The refolded protein was sequenced by the Edman protein sequencing
method on a Hewlett Packard G1000A automated protein sequencer (L. Dan-
gott, Protein Chemistry Laboratory, Texas A&M University). Aliquots of
rgpIFN- were prepared and stored at 80°C for testing the bioactivity. The
level of endotoxin in the folded recombinant protein was tested by the Limulus
amebocyte lysate assay (Associates of Cape Cod, Inc., Falmouth, MA) and was
found to be 0.075 endotoxin units/g (17 pg/g) IFN- and was much lower than
the acceptable concentration (100 pg/g) in commercially available recombinant
cytokines.
Induction of polyclonal antibody. Three New Zealand rabbits (Charles River
Breeding Laboratories, Inc., Wilmington, MA) were immunized subcutaneously
with 200 g of denatured gpIFN- in 500 l of phosphate-buffered saline (PBS)
mixed with 500 l of TiterMaxGold adjuvant (CytRx Corp., Atlanta, GA). The
adjuvant-antigen mixture was injected into five sites (0.2 ml/site). Beginning 4
weeks after the first immunization, the rabbits were boosted three times intra-
muscularly at 3-week intervals with the same dose of denatured protein-adjuvant.
The rabbits were bled both before and at regular intervals after immunization to
determine the antibody titer by Western blot analysis and were exsanguinated 5
weeks following the last booster. Sera obtained after centrifugation of blood at
1,520 g for 20 min were stored in small aliquots at80°C. The specificity of the
serum was tested by Western blot analysis.
Western blot analysis. Approximately 200 ng of the denatured protein eluted
from the Ni column or the folded protein was separated by SDS-PAGE with 10
to 20% Tris-Tricine precast gels under nonreducing conditions and stained by
Coomassie blue or SilverXpress (NOVEX-Invitrogen, Carlsbad, CA). The pro-
tein was transferred onto polyvinylidene difluoride membranes (Invitrogen) with
Tris-glycine transfer buffer (Invitrogen) for 1 h at 100 V. The WesternBreeze
chromogenic immunodetection kit (Invitrogen) was used to visualize the immu-
noreactive protein. Briefly, the blotted polyvinylidene difluoride membranes
were blocked with a solution containing Hammersten casein for 30 min at RT
and incubated in a primary antibody solution containing 1:1,000 and 1:5,000
dilutions of rabbit anti-rgpIFN- antiserum for 1 h and in a secondary antibody
solution (alkaline phosphatase-conjugated, affinity-purified anti-rabbit immuno-
globulin G [IgG]; Invitrogen) for 30 min. In order to develop the blots, the
antibody-bound membranes were incubated at RT with gentle agitation in a
solution containing 5-bromo-4-chloro-3-indolyl-1-phosphate (BCIP) and Nitro
Blue Tetrazolium. The filters were air dried and photographed.
Viral cytopathicity assay. The biological activity of the folded IFN- was
determined based on its ability to reduce the CPE of EMCV in guinea pig
fibroblast cell line 104C1 as described previously by us (51). The expanded cells
(3  104/100 l/well) were plated in flat-bottom 96-well plates in RPMI medium
(Irvine Scientific, Santa Ana, CA) without phenol red containing 4% fetal bovine
serum (FBS; Atlanta Biologicals, Norcross, GA), 100 U/ml penicillin (Irvine
Scientific), and 100 g/ml streptomycin (Irvine Scientific) and incubated at 37°C
for 24 h. Protein samples were added to the cells after making serial dilutions in
complete RPMI medium, and the plates were incubated overnight at 37°C. A
human lymphoblastoid IFN- (hIFN-, 200 U/ml; ICN Pharmaceuticals, Inc.,
Costa Mesa, CA) standard was used in each assay. The cells were infected with
the virus (multiplicity of infection [MOI], 0.03) for 30 h; the dye, a mixture of
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium mono-
sodium salt and 1-methoxy-5-methylphenazinium methyl sulfate, was added; and
the plates were incubated for 1.5 h at 37°C. The color reaction was stopped by
adding 1 N H2SO4, and the intensity of the color was measured at OD450 to
OD650 in a Dynatech MR5000 automated plate reader (Dynatech Laboratories,
Chantilly, VA). The net change in OD was calculated by subtracting the OD of
the test well from that of the infected control wells. The titers that showed 50%
CPE inhibition were calculated for both hIFN- and the test samples, and the
units of activity in the sample were expressed relative to the hIFN- standard.
Animals and BCG vaccination. Randomly bred Hartley strain guinea pigs
weighing 200 to 300 g were obtained from Charles River Breeding Laboratories,
Inc. (Wilmington, MA). The animals were housed individually in polycarbonate
cages in a temperature- and humidity-controlled environment; ambient lighting
was automatically controlled to provide 12-h light and 12-h dark cycles. Animals
were given commercial chow (Ralston Purina, St. Louis, MO) and tap water ad
libitum. All procedures were reviewed and approved by the Texas A&M Uni-
versity Laboratory Animal Care Committee. Guinea pigs were vaccinated intra-
dermally with 0.1 ml (103 viable units) of M. bovis BCG (Danish 1331 strain;
Statens Seruminstitut, Copenhagen, Denmark) in the left and right inguinal
regions. The lyophilized vaccine was reconstituted with Sauton’s medium (Stat-
ens Seruminstitut) just before use.
Harvesting of peritoneal cells. Guinea pigs were euthanized by intramuscular
injection of an overdose of sodium pentobarbital (Sleepaway; Fort Dodge Lab-
oratories, Inc.). The peritoneal cavity was opened aseptically, and resident cells
were harvested by flushing the peritoneal cavity three times with 20 ml of cold
RPMI medium (Irvine Scientific, Santa Ana, CA) containing 20 U of heparin.
The recovered cells were kept on ice. Cells were depleted of erythrocytes by
incubation in ACK lysing buffer (0.14 M NH4Cl, 1.0 mM KHCO3, 0.1 mM
Na2EDTA [pH 7.2 to 7.4]). The cells were washed in RPMI medium, and the
viable cells were counted by the trypan blue exclusion method. The cells were
suspended at 5  106/ml in RPMI medium supplemented with 2 M glutamine
(Irvine Scientific), 0.01 mM 2-mercaptoethanol (Sigma, St. Louis, MO), 100 U of
penicillin/ml (Irvine Scientific), 100 g of streptomycin/ml (Irvine Scientific), and
10% heat-inactivated FBS (Atlanta Biologicals). Cells (2 106) were cultured in
a 1-ml volume in polypropylene round-bottom tubes (Becton Dickinson, Frank-
lin Lakes, NJ) in the presence or absence of rgpIFN- (5 to 2,000 ng/ml) for 24
to 72 h to determine MHC class II expression. For other assays, cells were
allowed to adhere for 2 to 3 h in 24- or 96-well microtiter plates (Becton
Dickinson Labware, Franklin Lakes, NJ). Nonadherent cells were removed; the
monolayers were composed predominantly of macrophages (	95%), as visual-
ized by nonspecific esterase staining (50). These macrophage-enriched cells were
then stimulated with various concentrations of rgpIFN-.
MHC class II staining and flow cytometry. The peritoneal cells were stained
with monoclonal antibody against guinea pig MHC class II (Biosource Interna-
tional, Camarillo, CA). For each antibody or control, 5  105 cells were placed
in small polypropylene tubes and pelleted by centrifugation at 200 g for 10 min
at 4°C. The supernatant was removed, and the pellet was resuspended in 50 l
of PBS. FcR binding was effectively blocked by incubating the cell suspension in
10 l of (1 mg/ml) normal goat IgG (Sigma, St. Louis, MO) for 10 min before the
addition of 50 l of mouse anti-guinea pig MHC class II (1:10) antibody. Both
primary and secondary antibody dilutions were made in PBS containing 0.1%
goat IgG. The cells were then incubated for 1 h in ice on a shaker. At the end of
the incubation, cells were washed three times with Hanks balanced salt solution
(HBSS) containing 10% FBS at 200  g for 10 min. The pellet was resuspended
in a 1:10 dilution of the secondary antibody (fluorescein isothiocyanate-conju-
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gated AffiniPure goat anti-mouse IgG [heavy and light chains]; Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) and incubated for 1 h in ice on
a shaker. The cells were then washed two times and finally suspended in 300 l
HBSS containing 1% paraformaldehyde. Expression of MHC class II on mac-
rophages was determined by flow cytometry, with a FACScalibur and CellQuest
(Becton Dickinson Immunocytometry Systems, San Jose, CA) software for data
acquisition. Data analysis was performed in FlowJo (Treestar Inc., Ashland,
OR). A macrophage region was defined based on forward and side light scat-
tering characteristics, and univariate probability binning (43) was used to define
the MHC class-II positive macrophages based on the intensity of fluorescein
staining. In the MultiSample Comparison platform, the number of bins was set
to ensure an average of at least 10 events per channel in all samples being
compared, and a gate for the MHC class II-positive macrophages was defined.
The mean fluorescence intensity (MFI) of the MHC class II macrophages was
defined as the geometric MFI, expressed in arbitrary linear units, of the positive
population defined by probability binning.
Determination of nitrite production. Peritoneal cells were allowed to adhere
to 96-well microtiter plates for 2 to 3 h, and the nonadherent cells were removed.
Macrophages were incubated in the presence of rgpIFN- (5 to 500 ng/ml) for
24 h and subsequently infected with M. tuberculosis H37Rv (MOI, 0.1) for 24 to
72 h. The supernatants from these cultures were collected at regular time inter-
vals and tested for the presence of nitrite with the Griess reagent (8). Briefly, 50
l of supernatant was added in triplicate to a 96-well plate and mixed with an
equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthylethylenedia-
mine dihydrochloride, 2.5% H3PO4). The absorbance at 540 nm was measured in
a microplate reader with NaNO3 as a standard for determining the nitrite
concentration.
Effect on H2O2 production. The H2O2 production assay was based on the
horseradish peroxidase-dependent oxidation of phenol red by H2O2 as reported
earlier (40). Peritoneal cells from both naive and BCG-vaccinated guinea pigs
were plated in 96-well microtiter plates, and the nonadherent cells were removed
after 3 h. The cells were stimulated with rgpIFN- (5 to 500 ng/ml) for 2 to 3 h
and then infected with M. tuberculosis H37Rv (MOI, 0.1) for 24 to 48 h. At
appropriate time intervals, media were removed from the wells and 100 l of the
assay solution (28 mM phenol red [Sigma], 100 U/ml horseradish peroxidase type
II [Sigma]) in HBSS was added to the test wells. The assay solution containing
stimulants (phorbol myristate acetate [PMA; Sigma] at 100 ng/ml) or inhibitors
(100 to 200 M catalase; Sigma) was also added to the appropriate wells. The
plates were incubated for 1 h at 37°C in the presence of 5% CO2. The control
wells contained unstimulated and uninfected cells. After the incubation, the
reaction was stopped by addition of 10 l of 1 N NaOH to each well. The
standards were prepared by making twofold serial dilutions of 100 M H2O2
(Sigma) in the assay solution and adding 10 l of 1 N NaOH. The plates were
then allowed to equilibrate for 3 min, and the absorbance was measured in a
plate reader at 630 nm. The amount of H2O2 released by the rgpIFN--treated
cultures was calculated as nanomoles per milliliter from the standard curve.
Effect of rgpIFN- on intracellular growth of mycobacteria. The intracellular
growth of mycobacteria was determined by the incorporation of [3H]uracil by
metabolically active M. tuberculosis as reported by us previously (3). Peritoneal
cells from both naive and BCG-vaccinated guinea pigs were plated (3  105
cells/well) in 96-well microtiter plates in complete RPMI medium containing
10% FBS, and the nonadherent cells were removed after 3 h of incubation at
37°C. The cells were treated with various concentrations (50 to 1,000 ng/ml) of
rgpIFN- for 24 h, at the end of which medium was removed and the cells
washed once in antibiotic free RPMI medium. Macrophages were then infected
with M. tuberculosis H37Rv (MOI, 1:1) for 3 h, and the extracellular bacteria
were removed by washing two times with antibiotic-free medium. In some ex-
periments, rgpIFN- was added both before and after phagocytosis, and in other
experiments, the recombinant protein was added only after phagocytosis. In all
cultures, protein was present throughout the 7-day culture period. Infected
macrophages were then incubated in medium containing gentamicin (50 g/ml)
to inhibit the extracellular mycobacteria for 7 days at 37°C. The macrophages
were pulsed with 1 Ci of [3H]uracil for 24 h before harvesting. The mycobac-
teria were killed by incubating the plate at 80°C for 30 min and harvested with a
FilterMate harvester, and the [3H]uracil uptake was measured in a scintillation
counter (Beckman LS-1801).
Effect of rgpIFN- treatment on morphological changes. The changes in the
morphology of resident peritoneal macrophages after rgpIFN- (5 to 500 ng/ml)
treatment were visualized under an inverted microscope. Macrophages were also
cultured in collagen- or fibronectin-coated chamber slides (BD Biosciences,
Bedford, MA) in the presence of rgpIFN- and stained by the Diff-Quik staining
method (American Scientific Products, McGaw Park, IL).
Statistics. The differences between naive and BCG-vaccinated groups were
assessed by analysis of variance (ANOVA), and the differences between the
treated and untreated groups were examined by Student t test; values of P
 0.05
were considered statistically significant. There were 3 to 10 guinea pigs per
group, and each experiment was performed at least three times.
RESULTS
Purification of rgpIFN-. gpIFN- cDNA (GenBank acces-
sion number E25787) was subcloned into the expression vector
pQE30 THR and transformed into E. coli M15, and protein
expression was induced with IPTG for 5 h. An 18-kDa band in
the insoluble fraction was recognized as the putative His-
tagged gpIFN- by SDS-PAGE analysis and was purified by Ni
affinity chromatography. Figure 1 shows the Coomassie blue-
stained SDS-PAGE gel with a distinct band present at 18 kDa
in the crude CL (lane 2), which corresponds to the molecular
mass of gpIFN-; lanes 3 to 6 contain elution fractions (2 to 5)
following affinity chromatography; and lanes 7 and 8 contain
the folded protein (F). N-terminal sequencing of the recombi-
nant protein preparation yielded the sequence MRGSHHHH
HHGALVPRGXYYXQSRF. This corresponds to the pre-
dicted N-terminal sequence of His-tagged gpIFN- based on
the sequence analysis of the cDNA published earlier (21), thus
confirming the identity of the purified protein and suggesting
the lack of any other protein contaminants in the sample.
Sequence alignment of gpIFN- (GenBank accession num-
bers E25787 and Q8CGS0 and reference 21) with human, rat,
and mouse IFN- (GenBank accession numbers P01579,
P01581, and P01580, respectively) revealed 29% overall iden-
tity (Fig. 2A), with the human and gpIFN- sequences being
more closely related to each other (57.14% identity) than the
rat and mouse sequences (Fig. 2B).
FIG. 1. Coomassie blue-stained SDS-PAGE analysis of crude and
purified cell lysate, elution fractions, and folded rgpIFN-. The arrow
indicates an 18-kDa band in the insoluble fraction which was recog-
nized as a putative six-His–rgpIFN-. Lane 1 (MM), molecular mass
marker; lane 2, CL; lanes 3 to 6, elution fractions 2 to 5; lanes 7 and 8
(F), folded-protein preparations from two separate purifications.
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Induction of polyclonal antibody. The specificity of the rab-
bit antiserum was analyzed by Western blotting with the West-
ernBreeze chromogenic immunodetection kit. Figure 3 illus-
trates an 18-kDa band of gpIFN- in a Coomassie blue-stained
SDS-PAGE gel (panel A) and the identification of the protein
by the rabbit serum in the Western blotting (panel B). Poly-
clonal rabbit anti-gpIFN- at dilutions of 1:1,000 and 1:5,000
detected both denatured (D, immunizing protein) and folded
(F) rgpIFN- (200 ng/lane), with the reactivity stronger in the
denatured form. No reactivity was seen with preimmune serum
(Fig. 3B).
Viral neutralization activity. It has been well documented
that IFN- induces antiviral activity in both human and mouse
cells (26, 49). The biological activity of the folded rgpIFN-
protein was determined based on its ability to reduce a viral
(EMCV) CPE in guinea pig fibroblast cell line 104C1 by a
method we have published previously (51). Figure 4 shows the
results from the CPE inhibition assay of rgpIFN- on fibro-
blasts infected with the virus. The OD readings directly pro-
portional to cell viability indicated that hIFN- and the two
batches of rgpIFN- protected guinea pig fibroblasts against a
CPE. The level of inhibition was dose dependent and lower in
the rgpIFN- samples than in the human IFN- standard. The
activity was diluted out at lower concentrations in all of the
stimulants. The dilution titer that induced 50% CPE inhibition
was 26.3 for 100 U of the human IFN- standard, 22.8 for
rgpIFN- batch 1 (8/6/04), and 22.89 for batch 2 (8/9/04). The
titer for rgpIFN-, after conversion to units of activity based on
the human IFN- standard, was 17 U for batch 1 and 18 U for
batch 2. Thus, rgpIFN- expressed in E. coli induced antiviral
activity in a guinea pig cell line.
Effect on MHC class II expression. IFN- is known to up-
regulate MHC class II expression in human and mouse mac-
rophages (16, 38, 45). The upregulation of MHC class II ex-
pression on guinea pig peritoneal cells was examined following
incubation with doses of 5 to 2,000 ng/ml rgpIFN- for 24 to
72 h. The cells were stained for surface expression of MHC
class II molecules with a mouse anti-guinea pig MHC class II
antibody, and the MFI was determined by flow cytometry.
Figure 5 shows a representative histogram of MFI in macro-
phages from naive and BCG-vaccinated animals treated with
500 ng/ml rgpIFN- (panel A) and the ratio of MFI of stimu-
lated over unstimulated cultures treated with 5 to 2,000 ng/ml
protein (panel B). Treatment of cells from the naive animals
resulted in a minimal increase in the expression levels (
15%).
However, rgpIFN- at all doses induced an increase in MHC
class II expression in the BCG-vaccinated group (15 to 40%).
The level of expression was significantly enhanced in the cells
treated with 200 (P 
 0.05) and 500 (P 
 0.02) ng/ml of
rgpIFN- protein. Incubation of the cells with rgpIFN- for
FIG. 2. Protein sequence comparison of IFN- from different species. (A) ClustalW (version 1.82) alignment of the amino acid sequences of
the rat, mouse, guinea pig, and human IFN- precursor proteins (accession numbers P01581, P01580, Q8CGS0, and P01579, respectively).
Asterisks indicate positions displaying identical amino acid residues in all sequences in the alignment, colons indicate positions showing conserved
substitutions, and periods indicate positions displaying semiconserved substitutions. (B) Phylogram showing the relative evolutionary distances
among the primary structures of the IFN- proteins from the species indicated above. The branch lengths are proportional to the amount of
inferred evolutionary change.
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more than 24 h did not increase the level of MHC class II
expression (data not shown). Staining of the cells by the trypan
blue exclusion method revealed no cytotoxicity at the higher
doses of protein (data not shown).
Effect on nitrite production. Peritoneal macrophages from
naive and BCG-vaccinated guinea pigs were cultured with or
without rgpIFN- (50 to 1,000 ng/ml) for 24 h. M. tuberculosis
H37Rv (MOI, 0.1) was added, and cultures were incubated for
an additional 24 to 72 h. The supernatants from these cultures
were tested for the presence of nitrite by the Griess reaction at
regular time intervals. Infected macrophages did not produce
any nitrite when incubated with rgpIFN- at any of the con-
centrations tested during the 72-h incubation (data not shown).
Similarly, macrophages treated with IFN- alone also showed
no nitrite production.
Effect on H2O2 production. In order to determine whether
rgpIFN--treated macrophages generate H2O2, peritoneal
macrophages from naive and BCG-vaccinated guinea pigs
were incubated with 50 to 500 ng/ml of rgpIFN- for 3 h and
then infected with virulent M. tuberculosis for 24 to 48 h. At the
end of the incubation time, media were removed from the wells
and the assay solution containing phenol red and horseradish
peroxidase type II was added with or without PMA or catalase.
The increased absorbance at an alkaline pH was measured at
630 nm. Figure 6 shows the number of nanomoles of H2O2
produced by macrophages in response to IFN- (200 ng/ml)
for 3 h, M. tuberculosis (MOI, 0.1) for 24 h, or PMA (100
ng/ml) for 1 h. rgpIFN- at doses of 200 to 500 ng/ml induced
a significant increase in H2O2 production (P 
 0.05) in these
macrophages, and the maximum effect was seen in cells treated
with 200 ng/ml. The results indicated that macrophages from
naive animals were incapable of producing H2O2 after incuba-
tion with the recombinant protein and mycobacteria (Fig. 6A).
However, stimulation with PMA induced a significant (P 

0.05) increase in the production of H2O2 in these cells and the
effect was inhibited (P
 0.05) after the addition of catalase. In
contrast, macrophages from BCG-vaccinated guinea pigs
treated with 200 ng/ml rgpIFN- or M. tuberculosis (Fig. 6B)
alone produced significant amounts of H2O2 (P 
 0.05). The
level of H2O2 production was enhanced synergistically after
treatment with the combination of recombinant protein and M.
tuberculosis. Incubation with PMA also induced large amounts
of H2O2 in these macrophages, and the level was similar to that
obtained with the combination treatment. Addition of 100 M
catalase to the cultures neutralized the effect (Fig. 6B). There
was no further increase in H2O2 production in these macro-
phages after 48 h of stimulation with rgpIFN- or M. tubercu-
losis (data not shown).
Effect on intracellular growth of M. tuberculosis. IFN- is
known to activate mouse macrophages to kill M. tuberculosis
(11–13). In order to determine whether rgpIFN- would re-
strict the intracellular growth of M. tuberculosis, macrophages
from naive and BCG-vaccinated guinea pigs were cultured
with different doses of rgpIFN- for 24 h. The medium was
removed, fresh medium without antibiotics was added, and the
cultures were infected with M. tuberculosis for 3 h. Some mac-
rophage cultures were treated twice with the recombinant cy-
tokine, both before and after infection. rgpIFN- was present
throughout the 7-day culture period in these two groups. Fig-
FIG. 3. Identification of rgpIFN- by polyclonal antiserum (1:1,000
and 1:5,000 dilutions) from immunized rabbits. rgpIFN- (200 ng/well)
was loaded onto duplicate gels and run under nonreducing conditions.
One was visualized by Coomassie blue staining (A), and the other was
used as a template to compare the results from the Western blot assay
(B). MM, molecular mass marker; D, denatured protein used for
immunizing rabbits; F, folded protein.
FIG. 4. CPE inhibition assay of rgpIFN in 104C1 cells with EMCV.
A 100-l volume of the guinea pig fibroblast cell line suspension (3 
104 cells/well) was seeded into 96-well plates and incubated overnight.
On the following day, 50 l of two batches of rgpIFN- protein sam-
ples (40 to 60 g/ml) were serially diluted and added to each well and
incubated for an additional 20 h. Cells were then infected with EMCV
and incubated for 30 h. 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-dis-
ulfophenyl)-2H-tetrazolium monosodium salt and 1-methoxy-5-meth-
ylphenazinium methyl sulfate were used for color development, and
the reaction was stopped with 1 N H2SO4, and the OD450 and OD650
in each well were measured with a microplate reader for the test and
reference wavelengths. The amount of active protein was assessed by
preventing a virus-induced CPE in guinea pig cells with human IFN-
as the standard.
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ure 7 shows the [3H]uracil uptake by M. tuberculosis in mac-
rophages from naive (A) and BCG-vaccinated (B) guinea pigs.
rgpIFN- treatment reduced the intracellular growth of bac-
teria in the macrophages from both naive and BCG-vaccinated
animals. In the naive group, a significant reduction (P 
 0.0.05
to 0.007) in growth was observed at 50, 200, 500, or 1,000 ng/ml
of the recombinant protein given 24 h prior to infection with
M. tuberculosis compared to the untreated macrophages (Fig.
7A). Additional rgpIFN- added after infection (2x) had no
effect on bacterial growth. Moreover, no reduction in bacterial
growth was seen (Fig. 7A) when rgpIFN- was added to the
macrophage cultures after infection (P.I). The decrease in bac-
FIG. 5. Effect of rgpIFN- on MHC class II expression on peritoneal macrophages. Peritoneal cells from naive and BCG-vaccinated guinea pigs
were treated with rgpIFN- (5 to 2,000 ng/ml) for 18 to 24 h, and the cells were stained with monoclonal antibody against guinea pig MHC class
II. The MFIs of MHC class II-positive cells were determined by flow cytometry. The results are expressed in a histogram (A) as MFIs from a
representative experiment in which macrophages were treated with 500 ng/ml rgpIFN- for 24 h. The ratios of MFIs of stimulated over
unstimulated cultures are shown in panel B, and the results are the mean and standard error of the mean from three experiments. There were 5
to 10 animals per group. , P 
 0.05 compared with the untreated control group (ANOVA).
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terial growth varied from 0 to 57% in the naive macrophages
after IFN- treatment. In BCG-vaccinated animals (Fig. 7B),
the intracellular survival of M. tuberculosis was significantly
reduced (P 
 0.003 to 0.0002) after rgpIFN- treatment of
macrophages with 50 to 1,000 ng/ml protein added 24 h prior
to M. tuberculosis infection. The reduction in growth was 38 to
71% compared with the untreated cultures. The response was
only slightly enhanced when macrophages were treated with
two doses of 200 and 500 ng/ml protein both before and after
infection (2x). Unlike the naive animals, macrophages from
vaccinated animals were able to restrict the growth of M. tu-
berculosis significantly (P 
 0.003 and 0.0003) when rgpIFN-
(200 and 500 ng/ml) was added after infection (P.I) (Fig. 7B).
Thus, a single treatment with rgpIFN- restricted the survival
of intracellular bacteria in macrophages from both naive and
BCG-vaccinated guinea pigs. In the BCG-vaccinated animals,
rgpIFN- was able to reduce bacterial growth in macrophages
even when added after infection. The viability of macrophages
cultured in the presence of M. tuberculosis and rgpIFN- was
unaffected at 7 days, as confirmed by trypan blue staining of
macrophages (data not shown).
Effect on morphology of macrophages. We examined the
ability of rgpIFN- to induce morphological alterations in cul-
tured peritoneal cells. Figure 8 shows resident peritoneal cells
from naive (panels A and C) and BCG-vaccinated (panels B
FIG. 6. Effect of rgpIFN- on H2O2 production. Peritoneal mac-
rophages from naive (A) and BCG-vaccinated (B) guinea pigs plated
in 96-well microtiter plates were stimulated with rgpIFN- (200 ng/ml)
for 3 h and then infected with M. tuberculosis H37Rv (MOI, 0.1) for
24 h. Medium from the wells was removed, and 100 l of the assay
solution containing phenol red, horseradish peroxidase type II in
HBSS was added to the test wells. Some wells contained stimulants
(PMA, 100 ng/ml) or inhibitors (100 M catalase [Cat.]). The reaction
was stopped after 1 h by the addition of 10 l of 1 N NaOH, and the
absorbance was measured in a plate reader at 630 nm. The results are
the mean  the standard error of the mean from three different
experiments involving at least three animals per group and are ex-
pressed as nanomoles per milliliter of H2O2 calculated from a standard
curve. , P 
 0.05 compared with the untreated control (ANOVA).
FIG. 7. Effect of rgpIFN- on intracellular growth of M. tubercu-
losis by [3H]uracil uptake. Macrophages from naive (A) and BCG-
vaccinated (B) guinea pigs were treated with various doses (50 to 1,000
ng/ml) of rgpIFN- for 24 h. The RPMI medium was removed, fresh
medium without antibiotics was added, and the cultures were infected
with M. tuberculosis (MOI, 1:1) for 3 h. The extracellular bacteria were
removed, and some cultures were further treated with 200 or 500 ng/ml
protein or treated with 200, 500, or 1,000 ng/ml only after infection.
The [3H]uracil uptake by viable M. tuberculosis was measured on day 7
and is expressed as counts per minute (CPM). The results represent
the mean the standard error of the mean from five experiments. The
differences between naive and BCG-vaccinated groups were examined
by ANOVA, and differences between means were compared by Stu-
dent’s t test (†, P 
 0.05; , P 
 0.005; , P 
 0.0005 [in comparison
with the respective untreated cultures]). P.I, postinfection.
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and D) guinea pigs cultured with or without rgpIFN- (50
ng/ml) for 16 h. rgpIFN- induced the formation of multiple
spindle-shaped macrophages by 16 h in culture, from both
naive (Fig. 8C) and BCG-vaccinated (Fig. 8D) guinea pigs,
although the effect was more apparent in the naive animals.
Figure 9 shows resident peritoneal macrophages from naive
(panels A and C) and BCG-vaccinated (panels B and D)
guinea pigs stained by the Diff-Quik method. Macrophages
from BCG-vaccinated guinea pigs cultured in chamber slides in
the presence of various doses of rgpIFN- (50 to 500 ng/ml) for
16 h, followed by Diff-Quik staining, were more vacuolar in
appearance (panel D), especially at higher doses (500 ng/ml),
suggesting that they are more activated than the cells from the
naive group (panel C). Interestingly, as little as 5 ng of
rgpIFN- protein was capable of inducing this effect in mac-
rophages and the effect was consistently observed with all
doses tested (data not shown).
DISCUSSION
IFN- is a pleiotropic molecule involved in multiple aspects
of the immune response, including the enhancement of antigen
presentation through MHC class I and II molecules, activation
of phagocytic cells to produce effector molecules such as reac-
tive oxygen and nitrogen intermediates, and the induction of
bactericidal activity (15, 16, 27, 38) in macrophages. This is the
first report of the production, purification, and characteriza-
tion of rIFN- from the guinea pig. IFN- was produced in E.
coli after subcloning the mature coding region of gpIFN- into
the pQE30-THR expression vector. rgpIFN- was identified as
FIG. 8. Effect of rgpIFN- on the morphology of resident peritoneal cells. Total peritoneal cells (106/well) from naive and BCG-vaccinated
guinea pigs were cultured in the presence of rgpIFN- (50 ng/ml) for 18 h. Photomicrographs show cells from naive guinea pigs left untreated
(A) or treated (C) with rgpIFN- and cells from BCG-vaccinated guinea pigs left untreated (B) or treated (D). Note the spindle-shaped
macrophages in the IFN--treated groups (arrows; magnification, 200). Results are representative of multiple experiments involving several
animals.
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an 18-kDa band in the insoluble fraction and was confirmed by
N-terminal sequence analysis. Although the protein was pro-
duced in the insoluble fraction, purification steps in the ab-
sence of denaturant resulted in the production of folded bio-
active protein. The deduced sequence alignment of rgpIFN-
protein revealed an overall identity with the mouse, rat, and
human sequences of 29%; however, its identity with human
IFN- was 57% (Fig. 2). Western blot analysis confirmed that
rabbit polyclonal antisera raised against the denatured protein
could detect both denatured and folded bioactive rgpIFN-
(Fig. 3).
The distinctive antiviral activity of IFN- is well documented
(26, 49). In the present study, the bioactivity of the recombi-
nant protein was tested for the ability to protect the guinea pig
fibroblast cell line from EMCV infection. The results clearly
indicate that rgpIFN- was effective in preventing a CPE in
this cell line. The units of IFN activity in two different recom-
binant protein batches were quite comparable in our viral
cytopathicity assay (Fig. 4). An earlier study in our laboratory
(51) demonstrated that culture supernatants from spleen cells
from BCG-vaccinated guinea pigs stimulated with either puri-
fied protein derivative or MY-1 (an immunostimulatory oli-
goDNA extract from M. bovis BCG) had antiviral activity in
this bioassay. The IFN titers, as defined by 50% CPE inhibi-
tion, and the units of activity in terms of the human IFN-
standard in these two studies are quite comparable.
IFN- is known to play a central role in resistance against
mycobacteria by activating macrophages to produce effector
molecules such as reactive nitrogen or oxygen intermediates
(11, 13, 37). Although nitric oxide (NO) has been clearly iden-
tified as an effector molecule in the killing of mycobacteria in
the mouse (11, 12, 17), its role in the induction of intracellular
killing by human macrophages in vitro is still debatable (7, 48).
Interestingly, in the present study, rgpIFN- was incapable of
inducing the production of NO from peritoneal macrophages,
even after infection with virulent M. tuberculosis. Either the
dose of the protein or the duration of treatment used in the
present study may not be optimum for the production of NO in
vitro by guinea pig macrophages, although under similar ex-
perimental conditions, mouse macrophages are known to pro-
duce nitrite in response to IFN- alone (11, 12, 19). It is also
possible that guinea pig macrophages require stimulation with
FIG. 9. Effect of rgpIFN- on the morphology of resident peritoneal macrophages. Cells from naive (A and C) and BCG-vaccinated (B and
D) guinea pigs were cultured as described in Materials and Methods in the presence of IFN- (50 to 500 ng/ml) in chamber slides and then stained
by the Diff-Quik method. Shown are treated (500 ng/ml) cells from naive (C) and BCG-vaccinated (D) guinea pigs showing vacuoles (arrows) in
the macrophages. Magnification, 600. There were three guinea pigs per group, and the experiments were repeated several times.
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other cytokines in addition to IFN- to produce NO. A previ-
ous study in our laboratory demonstrated that guinea pig al-
veolar macrophages were not able to produce reactive nitrogen
metabolites, even after stimulation with lipopolysaccharide
(LPS) in combination with recombinant murine or human
IFN, infection with Listeria monocytogenes, or supernatants
obtained from concanavalin A-stimulated lymphocytes (52).
This finding is quite consistent with earlier studies with guinea
pigs in which peritoneal macrophages were not able to produce
detectable NO after virulent and avirulent Legionella pneumo-
phila infection (30). Interestingly, inducible NO synthase ac-
tivity has been detected in the guinea pig ileum, after hapten
administration in the cochlea of guinea pigs, or in the inflam-
matory cells of guinea pigs with chronic allergic airway inflam-
mation (34, 35, 42). This suggests that mechanisms other than
toxic nitrogen intermediates may be responsible for mycobac-
terial control in the vaccinated guinea pig. On the contrary,
rgpIFN- and virulent M. tuberculosis, alone or in combination,
induced the production of H2O2 in macrophages obtained
from BCG-vaccinated guinea pigs (Fig. 6). IFN- has been
shown to activate murine peritoneal macrophages and human
alveolar macrophages to produce H2O2 (37, 44). We have
reported that guinea pig neutrophils produced superoxide af-
ter incubation with rgpIL-8, and this was stimulated further by
exposure of neutrophils to LPS or attenuated M. tuberculosis
H37Ra (32).
Production of H2O2 by macrophages from BCG-vaccinated
guinea pigs after rgpIFN- treatment was associated with a
reduction in the intracellular survival of M. tuberculosis (Fig.
7). Interestingly, macrophages from naive animals were inca-
pable of producing H2O2 after 3 h of rgpIFN- treatment;
however, macrophages from both naive and vaccinated ani-
mals were able to restrict mycobacterial growth after rgpIFN-
treatment. The recombinant protein at very low doses was
capable of inducing the antimycobacterial effect in macro-
phages; however, rgpIFN- had to be added before M. tuber-
culosis infection in order for macrophages from naive animals
to restrict bacterial growth. In contrast, macrophages from
BCG-vaccinated animals responded by controlling intracellu-
lar M. tuberculosis even when rgpIFN- was added after infec-
tion. IFN- is a potent activator of mouse macrophages (2,
11–14), and this activation is followed by an upregulation of
MHC class II expression and production of effector molecules
such as reactive oxygen and nitrogen intermediates, followed
by effective intracellular killing of mycobacteria (8, 12, 15, 27).
On the contrary, it is not clear yet whether human macro-
phages can be activated by IFN- to be bactericidal (7, 36, 37).
The fact that macrophages from vaccinated guinea pigs re-
spond differently to rgpIFN- in vitro indicates that they are
already in some state of activation or heightened receptivity to
activating signals after vaccination, and a short exposure to
rgpIFN- induces production of H2O2 in these macrophages
compared to the unvaccinated group. Perhaps macrophages
from naive animals need a prolonged exposure to recombinant
protein before they can be activated to produce effector mol-
ecules. Recently, reports from our laboratory have shown that
rgpTNF- stimulated IL-12 mRNA expression in alveolar
macrophages and addition of anti-TNF- polyclonal antibody
increased the intracellular survival of both attenuated and vir-
ulent strains of M. tuberculosis (3).
It is well established that IFN- upregulates expression of
cell surface molecules such as MHC class II in mice and hu-
mans (7, 37). Our results demonstrate that rgpIFN- treatment
increased MHC class II expression in peritoneal macrophages
obtained from BCG-vaccinated guinea pigs (Fig. 5). Even low
doses of rgpIFN- (5 to 50 ng/ml) were capable of inducing this
effect, which diminished at higher doses (	1,000 ng/ml) of the
protein. Interestingly, rgpIFN- caused only minimal increases
in MHC class II expression in macrophages obtained from
naive guinea pigs. These results confirm that rgpIFN- purified
from E. coli in our laboratory is capable of activating guinea
pig macrophages by upregulating MHC class II expression.
rgpIFN- at low doses induced dramatic changes in the mor-
phology of macrophages. The macrophages assumed a spindle
shape in less than 18 h of treatment, while untreated cells were
uniformly round (Fig. 8). Although this phenomenon was more
apparent in the macrophages from naive animals, cells from
BCG-vaccinated guinea pigs also responded in a similar man-
ner. The rgpIFN--treated macrophages from BCG-vacci-
nated guinea pigs also appeared more vacuolar, indicating that
they might have been more activated than the treated cells
from the naive group (Fig. 9). This is consistent with our earlier
findings that macrophages from BCG-vaccinated animals had
enhanced IL-1, RANTES, IL-8, and TNF- mRNA levels
compared to cells from nonvaccinated animals following stim-
ulation with PMA and LPS or infection with virulent or atten-
uated M. tuberculosis (20, 28, 31). Interestingly, increased
MHC class II expression, production of H2O2, and an in-
creased ability to control intracellular survival of M. tubercu-
losis even when rgpIFN- was added after infection were ob-
served only in macrophages from BCG-vaccinated animals,
which further confirms that these macrophages are more acti-
vated or more susceptible to activation than cells from naive
guinea pigs. These results are consistent with those from a
previous report that demonstrated that BCG infection of mice
induced activated macrophages in the peritoneal cavity and
these macrophages killed tumor targets more effectively than
cells from uninfected mice (10).
These results clearly indicate that the rgpIFN- produced in
our laboratory is capable of inducing antiviral activity, upregu-
lation of MHC class II expression, production of H2O2, inhi-
bition of intracellular growth of virulent M. tuberculosis, and
morphological changes in macrophages. The biologic activity
of rgpIFN- is not due to LPS contamination, as the endotoxin
level in our protein samples was much lower than that present
in commercial preparations. The availability of rgpIFN- will
contribute to the elucidation of the mechanisms of BCG-in-
duced resistance in the guinea pig model of pulmonary tuber-
culosis. We are currently developing monoclonal antibodies
against rgpIFN- so that quantitative assays of protein produc-
tion may be applied in this model. Such studies will be valuable
in identifying and validating correlates of protection in vacci-
nated guinea pigs and contribute to the screening of new vac-
cine candidates against tuberculosis.
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